Coste y manejo de las crisis asmáticas atendidas en atención primaria (estudio COAX)

París, Jesús Molina; García, Gabriel; Corbella, E. Calvo; Toña, K. Naberan; Álvarez, M.A. Lobo

doi:10.1157/13075924

Cited by 7 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standard pharmacological treatments to control the disease include short and long acting ß2-agonists, inhaled and oral corticosteroids, and other therapies such as anticholinergic or biologic drugs that can be of interest for certain patients or situations. Despite the availability of effective treatment, there is compelling evidence of suboptimal control of asthma patients with asthma attacks in the real world, with important implications for the use of costly health care resources ( Molina París et al, 2005 ; Peters et al, 2006 ; Martínez-Moragón et al, 2009 ). Inadequate asthma management is linked to increased risk of exacerbation, emergency room visits and hospital admissions, and higher mortality.…”

Section: Introductionmentioning

confidence: 99%

Real-World Patterns of Pharmacotherapeutic Management of Asthma Patients With Exacerbations in the Spanish National Health System

et al. 2020

View full text Add to dashboard Cite

Background: Little is known about the real1world characteristics of asthma patients with exacerbations or their pharmacotherapeutic management. We described the sociodemographic and clinical characteristics, and the patterns of short and long-term management of asthma attacks, in a population-wide cohort of exacerbators in the region of Valencia, Spain. Methods: We selected asthma patients with at least one exacerbation in 2015 and 2016, we classified them according to their patterns of exacerbations in the 4 years previous to the index exacerbation and their therapeutic step at baseline based on medication received in the previous year. We described the short and long-term pharmacological management of the index exacerbation. Results: 18,714 patients experienced at least one exacerbation. The majority had no previous exacerbation (46.5%), or exacerbated in only one of the years (26.8%). 2.9% had attacks every single year, 25.7% of whom only received rescue medication at baseline. 29.5% of patients without previous exacerbation received maintenance therapy at baseline. Shortly following the index exacerbation, 2,461 patients (13.1%) did not receive any asthma prescription. Among those treated, 70.3% were prescribed a maintenance therapy, 62.4% received a rescue medication, and 30.5% received an oral corticoid. Throughout the year following the index exacerbation, most patients remained in their baseline therapeutic step. Conclusions: Most patients that exacerbate present very mild to mild forms of the disease or low levels of treatment and most exacerbations are managed in primary care. These insights may help to refine strategies for improving asthma control in the population.

show abstract

Section: Introductionmentioning

confidence: 99%

Real-World Patterns of Pharmacotherapeutic Management of Asthma Patients With Exacerbations in the Spanish National Health System

et al. 2020

View full text Add to dashboard Cite

show abstract

El coste del asma persistente de moderada a grave en España: impacto de la introducción de beclometasona/formoterol

Darbà

Restovic

2008

Pharmacoecon. Span. Res. Artic.

View full text Add to dashboard Cite

Crisis asmáticas e hiperreactividad bronquial en un servicio de urgencias de atención primaria

Durante

2009

Atención Primaria

View full text Add to dashboard Cite

Coste y manejo de las crisis asmáticas atendidas en atención primaria (estudio COAX)

Abstract: Mean cost of each asthma attack treated in primary care was 166.7 (95% CI, 146.5-192.3), of which 80% were direct costs and 20% indirect costs.

Cited by 7 publications

References 14 publications

Real-World Patterns of Pharmacotherapeutic Management of Asthma Patients With Exacerbations in the Spanish National Health System

Real-World Patterns of Pharmacotherapeutic Management of Asthma Patients With Exacerbations in the Spanish National Health System

El coste del asma persistente de moderada a grave en España: impacto de la introducción de beclometasona/formoterol

Crisis asmáticas e hiperreactividad bronquial en un servicio de urgencias de atención primaria

Contact Info

Product

Resources

About